Abstract
For intracellular Chlamydiaceae, there is no need to withstand osmotic challenges, and a functional cell wall has not been detected in these pathogens so far. Nevertheless, penicillin inhibits cell division in Chlamydiaceae resulting in enlarged aberrant bodies, a phenomenon known as chlamydial anomaly. D-alanine is a unique and essential component in the biosynthesis of bacterial cell walls. In free-living bacteria like Escherichia coli, penicillin-binding proteins such as monofunctional transpeptidases PBP2 and PBP3, the putative targets of penicillin in Chlamydiaceae, cross-link adjacent peptidoglycan strands via meso-diaminopimelic acid and D-Ala-D-Ala moieties of pentapeptide side chains. In the absence of genes coding for alanine racemase Alr and DadX homologs, the source of D-Ala and thus the presence of substrates for PBP2 and PBP3 activity in Chlamydiaceae has puzzled researchers for years. Interestingly, Chlamydiaceae genomes encode GlyA, a serine hydroxymethyltransferase that has been shown to exhibit slow racemization of D- and L-alanine as a side reaction in E. coli. We show that GlyA from Chlamydia pneumoniae can serve as a source of D-Ala. GlyA partially reversed the D-Ala auxotrophic phenotype of an E. coli racemase double mutant. Moreover, purified chlamydial GlyA had racemase activity on L-Ala in vitro and was inhibited by D-cycloserine, identifying GlyA, besides D-Ala ligase MurC/Ddl, as an additional target of this competitive inhibitor in Chlamydiaceae. Proof of D-Ala biosynthesis in Chlamydiaceae helps to clarify the structure of cell wall precursor lipid II and the role of chlamydial penicillin-binding proteins in the development of non-dividing aberrant chlamydial bodies and persistence in the presence of penicillin.
Introduction
Acute and chronic diseases caused by Chlamydiaceae are a global health problem. The Gram-negative obligate intracellular pathogens depend on eukaryotic host cells to maintain their unique biphasic developmental cycle. One elusive phenomenon of the chlamydial biology has fascinated researches for two decades: for endobacteria, such as Chlamydiaceae, there is no need to resist osmotic challenges and a functional cell wall has not been detected in these pathogens so far (McCoy and Maurelli, ). Nevertheless, in the evolutionary process of adaptation to the host environment, Chlamydiaceae species conserved in their reduced genomes a nearly complete cell wall precursor biosynthesis pathway (Figure 1) and antibiotics that target cell wall biosynthesis are active (McCoy and Maurelli, ). Penicillin has no bactericidal effect, as seen in free-living bacteria, but induces a reversible state of persistence in Chlamydiaceae that is characterized by the formation of viable, enlarged, reticulate bodies. These persisting cells are called aberrant bodies (AB) and show resistance to azithromycin (Wyrick and Knight, ), the first-line treatment for chlamydial infections (CDC, ). Beta-lactam induced formation of non-dividing ABs has been observed in cell culture (Skilton et al., ) as well as in vivo (Phillips Campbell et al., ).
Figure 1
In free-living bacteria, cell division must be highly coordinated with cell wall biosynthesis to maintain cell integrity. The need for tightly interconnecting both cell biological processes may be reflected by the partial overlap of components from both multi-protein machineries; e.g., the transpeptidase PBP3 (FtsI) is essential for the incorporation of cell wall building blocks at the septal cell wall and for cell division.
The bacterial cell wall consists of peptidoglycan, a polymer of long chains with alternating sugar units of N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc), which are cross-linked via flexible peptide bridges. Peptidoglycan is found in all eubacteria with the exception of some obligate intracellular species. Biosynthesis of peptidoglycan takes place in three stages (Figure 1). In the cytoplasm, six enzymes (MurA to MurF) catalyze the formation of the soluble precursor UDP-MurNAc-pentapeptide. Notably, the precursor contains D-Ala in positions 4 and 5 of the pentapeptide moiety. D-alanine is a unique and essential component in the biosynthesis of bacterial cell walls. The non-proteinogenic amino acid is synthesized by alanine racemases Alr and DadX and ligated by Ddl to form D-Ala-D-Ala. The dipeptide is attached to the amino acid in position 3 by the action of MurF to complete the pentapeptide side chain. In the first membrane-linked step, MraY catalyzes the synthesis of lipid I by transferring UDP-MurNAc-pentapeptide to the lipid carrier bactoprenol-phosphate (undecaprenyl-P). With the addition of UDP-GlcNAc, MurG synthesizes lipid II, the completed peptidoglycan cell wall building block. Lipid II is then translocated by the flippase FtsW to the outside of the cell and incorporated into the peptidoglycan network by the action of penicillin-binding proteins (PBPs) which exhibit transglycosylase and DD-transpeptidase activities.
The human cytosolic Pattern Recognition Receptors, Nod1 and Nod2, sensing bacterial cell wall fragments, recognize intracellular C. pneumoniae and subsequently mediate activation of the transcription factor NFkB which plays a key role in regulating the immune response to infection (McCoy and Maurelli,
A nearly complete lipid II biosynthesis pathway has been found in genomes of Chlamydiaceae (Figure 1) (McCoy and Maurelli,
We proposed that retaining biosynthesis of lipid II in cell wall-lacking “minimal bacteria,” like Chlamydiaceae, may reflect a vital role of the lipid II pathway in prokaryotic cell division (Henrichfreise et al.,
We searched chlamydial genomes for genes encoding other PLP dependent proteins and found serine hydroxymethyltransferase GlyA to be conserved in all chlamydial genera. Serine hydroxymethyltransferases are found in eu- and prokaryotes and are well known for their function in reversible interconversion of serine and glycine using tetrahydrofolate as the one-carbon carrier. In addition, the enzymes show a particularly broad reaction specificity and catalyze other side reactions typical for PLP dependent enzymes, such as decarboxylation, transamination and retroaldol cleavage (Contestabile et al.,
The aim of this study was to analyze GlyA as a potential source of D-Ala in Chlamydiaceae.
Here, we demonstrate that GlyA from C. pneumoniae is capable of the racemization of alanine in vivo and in vitro implicating that the enzyme can substitute for the absent alanine racemases and that D-Ala is self-synthesized in Chlamydiaceae.
Results
Racemization of alanine in chlamydiae
Using BLAST alignments, we searched Chlamydiaceae and enviromental chlamydiae genomes to identify genes coding for orthologs of E. coli PLP cofactor-requiring enzymes known to confer alanine racemization activity (Table 1). In contrast to the Chlamydiaceae and Simkania, the three environmental chlamydiae genera Parachlamydia, Protochlamydia, and Waddlia harbored one ortholog of the Alr or DadX alanine racemases. GlyA was the only enzyme to be encoded in Chlamydiaceae and in all enviromental chlamydiae.
Table 1
| E. coli | Cpn | Ctr | Pac | Pam | Wch | Sne |
|---|---|---|---|---|---|---|
| Alr (alanine racemase) | – | – | – | pc0631 (3e–34) | wcw_0679 (1e–32) | – |
| DadX (alanine racemase 2) | – | – | PUV_23750 (2e–28) | – | – | – |
| GlyA (serine hydroxymethyltransferase) | CPn0521 (2e–107) | CT432 (2e–108) | PUV_05830 (6e–118) | pc0444 (3e–107) | wcw_1457 (2e–117) | SNE_A20 270 (1e–114) |
| MetC (cystathionine beta-lyase) | – | – | PUV_18690 (2e–40) | – | wcw_1145 (4e–40) | – |
PLP cofactor-requiring enzymes involved in biosynthesis of D-Ala.
Locus tags of genes coding for enzymes involved in biosynthesis of D-Ala are shown for two exemplary Chlamydiaceae and for environmental chlamydiae species. The expected (E) values of BLAST P alignments are listed in brackets. E. coli, Escherichia coli W3110 (NC_007779.1); Cpn, Chlamydia pneumoniae CWL029 (NC_000922); Ctr, Chlamydia trachomatis D/UW-3/Cx (NC_000117); Pac, Parachlamydia acanthamoebae UV-7 (NC_015702.1); Pam, Protochlamydia amoebophila UWE25 (NC_005861.1); Wch, Waddlia chondrophila WSU 86-1044 (NC_014225.1); Sne, Simkania negevensis Z (NC_015713.1).
In vivo activity of GlyA from C. pneumoniae
In the absence of a tractable system to genetically manipulate C. pneumoniae we tested whether heterologous expressed C. pneumoniae GlyA (GlyACp) shows an effect on the D-Ala auxotrophic phenotype of an E. coli Δ alrΔdadX racemase double mutant strain. Our experiments in liquid and solid culture revealed that chlamydial GlyA did not completely reverse the need of exogenous D-Ala of the racemase mutant strain but favored its growth under D-Ala limited conditions (Figure 2). These findings suggest that GlyACp is a functional alanine racemase and capable of generating D-Ala in E. coli.
Figure 2

GlyACp exhibits in vivo activity in an E. coli racemase double mutant. A temperature sensitive Δ alrΔ dadX E. coli double mutant was transformed with pET21b-glyACp to allow for the expression of GlyACp in the cytoplasm. Independently generated transformants (1–3 containing pET21b-glyACp and 4–6 containing the empty vector) were grown on solid (A) or in liquid (B) LB medium under limited D-Ala growth conditions at 42°C. LB medium was supplemented with 5 mg/L D-Ala, 50 μM of cofactor PLP, 25 μg/ml thymine and 50 μg/ml ampicillin. Expression of GlyACp was induced by the addition of 0.1 mM IPTG.
Recombinant GlyACp has L-alanine racemase activity
To investigate the potential alanine racemase activity of the serine hydroxymethyltransferase GlyA from C. pneumoniae, we overexpressed recombinant GlyACp in E. coli and purified the Strep-tagged protein. In vitro activity of GlyACp was tested in a D-amino acid oxidase coupled enzymatic assay containing L-Ala and cofactor PLP. Alanine racemase from Bacillus stearothermophilus served as positive control. D-Ala that was produced by GlyA was converted to pyruvate by the activity of D-amino acid oxidase (DAAO) and colorimetrically quantified. The chlamydial GlyA converted L-Ala to D-Ala in vitro exhibiting weak racemase activity in comparision to the enzyme from B. stearothermophilus (Figure 3).
Figure 3

The purified serine hydroxymethyltransferase GlyACp has alanine racemase activity. In vitro activity of recombinant GlyACp was tested in a coupled enzymatic assay containing L-Ala and cofactor PLP. D-Ala that was produced by 1 μg GlyA or Bst racemase was converted to pyruvate by the activity of DAAO and colorimetrically quantified. (DCS: D-cycloserine; Bst racemase: alanine racemase from B. stearothermophilus).
GlyACp racemase activity is sensitive to D-cycloserine
D-cycloserine is a structural analog of D-Ala and competitively inhibits activity of alanine racemases and D-Ala ligases from free-living bacteria (Strominger et al., 1960; Lambert and Neuhaus,
Discussion
The source of D-Ala in Chlamydiaceae and thus the presence of the transpeptidation substrates for PBPs is a crucial aspect of the chlamydial anomaly that will help to gain understanding of the penicillin induced persistence in these human pathogens. Penicillin and other beta-lactams structurally mimic the D-Ala-D-Ala terminus of the pentapeptide side chain of the lipid II cell wall building blocks and are recognized by the active sites of DD-transpeptidase PBPs. Beta-lactams are active against Chlamydiaceae in cell culture (McCoy and Maurelli,
For E. coli, besides the constitutive expressed Alr racemase and the catabolic DadX racemase, two other PLP dependent enzymes involved in the methionine pathway have been shown to confer L-Ala racemization as a side reaction. Overexpressed cystathionine beta-lyase MetC completely reversed the D-Ala auxotrophic phenotype of an E. coli racemase double mutant whereas racemase co-activity of serine hydroxymethyltransferase GlyA was not sufficient to allow for growth on D-Ala lacking medium (Kang et al.,
We demonstrated L-Ala racemase activity for the GlyA enzyme from C. pneumoniae in vivo in an E. coli racemase double mutant and characterized the purified protein in vitro. Moreover, we identified GlyA as a second target of D-cycloserine besides MurC/Ddl in Chlamydiaceae.
Our results implicate that the enzyme can substitute for the absent alanine racemases and that D-Ala is present and self-synthesized in Chlamydiaceae. The observed weak alanine racemase activity of GlyACp cannot completely compensate D-Ala requirements of the E. coli racemase mutant to build a functional cell wall but might be sufficient to produce D-Ala in amounts that maintain the lipid II biosynthesis pathway in the cell wall-lacking Chlamydiaceae for the proposed functions of the cell wall precursor in co-ordination of cell division and modulation of the host immune response. Future research toward the elucidation of the chlamydial anomaly will include the isolation and structural characterization of lipid II building blocks and biochemical analysis of the penicillin binding proteins PBP2 and PBP3, the putative targets of penicillin whose activity depends on the presence of D-Ala-D-Ala in the pentapeptide side chain of lipid II.
Like other effectors, such as interferon-γ and tumor necrosis factor-α, penicillin can be used to induce persistence as an experimental tool to study chlamydiae/host interactions. Knowledge of the underlying mechanisms of penicillin induced formation of ABs will help to assess these results on the pathogenicity of Chlamydiaceae.
Moreover, analysis of the molecular biology of penicillin induced persistence is important to improve understanding of long-term infection in patients in particular as to the role of chlamydial cell wall precursors in immune modulation and refractory of ABs to anti-chlamydial agents.
Materials and methods
Bacterial strains and growth conditions
E. coli JM83 harboring the GlyACp expression vector was grown on Luria Bertani (LB) agar plates containing 30 μg/ml chloramphenicol and 100 μg/ml ampicillin, respectively. The temperature sensitive E. coli Δ alrΔ dadX racemase double mutant TKL-10 was maintained on LB agar plates containing 25 μg/ml thymine.
In vivo complementation
E. coli TKL-10 Δ alrΔ dadX was transformed with pET21b-glyACp and grown in liquid or on solid LB medium supplemented with 5 mg/L D-Ala, 50 μM PLP, 25 μg/ml thymine, 50 μg/ml ampicillin and 0.1 mM IPTG at 42°C. For each experiment three independently generated transformants were used and controls with E. coli TKL-10 Δ alrΔ dadX harboring the empty pET21b vector were carried out.
Cloning of glyA
The glyA gene from C. pneumoniae GiD was amplified by PCR using primer glyACp_f (5′-ATGGTAGGTCTCAGGCCTTGCTAAAAGTTTTTGAGAAATTTAAGA-3′) and glyACp_r (5′-ATGGTAGGTCTCAGCGCTAACTAAAGCTTCTAAATCAATTTCAGG-3′) and cloned into pASK-IBA2c (IBA, Germany) using the BsaI restriction site to generate an N-terminal OmpA-leader peptide fused, C-terminal Strep-tagged protein for periplasmic overproduction. For cytoplasmic expression in complementation assays, glyA was amplified with primers glyACp_pET21_f (5′-CGTCTTTAGAAGCATATGCTAAAAG-3′) and glyACp_pET21_r (5′-GTCTCTGCGGCCGCAACTAAAGCTTC-3′) and cloned into pET21b (Novagen, VWR, Germany) using NdeI and NotI restriction sites.
Overproduction and purification of GlyACp
E. coli JM83 cells, transformed with pASK-IBA2c-glyACp, were grown in no salt LB in presence of 30 μg/ml of chloramphenicol, 250 mM sucrose and 50 mM L-serine at 30°C. After induction at an OD600 of 1.2 with 200 ng/ml anhydrotetracyline (AHT), 50 μM PLP and 200 μM of folinic acid were added and the cells were incubated for 4 h at 25°C. The purification of GlyACp was performed using the protocol for cleared lysates recommended by the manufacturer (IBA, Germany) with small modifications: the buffers contained 2% N-lauroylsarcosine (or 0.1% N-lauroylsarcosine in the washing and elution buffer), 2 mM 1,4-dithiothreitol (DTT) and 50 μM PLP. Purity of the protein was controlled using SDS-PAGE.
In vitro GlyACp activity assay
Racemase activity of GlyACp was determined in a DAAO coupled enzymatic assay system as described previously with slight modifications (Francois and Kappock,
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Statements
Acknowledgments
We are grateful to Katja Mölleken for providing us with C. pneumoniae DNA and thank Fabian Grein and Jennifer Vollmer for fruitful discussions. Stefania De Benedetti holds a fellowship from the NRW International Graduate Research School Biotech-Pharma. Henrike Bühl and Christian Otten received a PhD fellowship from the Jürgen Manchot foundation. Ahmed Gaballah was associated member of the NRW International Graduate Research School Biotech-Pharma and received a PhD fellowship from the DAAD. Beate Henrichfreise was supported by the European Union (“New Antimicrobials” project, people programme, FP7). Support was received by the intramural funding scheme of the Medical Faculty of Bonn, BONFOR, and the Fonds der Chemischen Industrie. Hans-Georg Sahl and Beate Henrichfreise are members of the DFG Cluster of Excellence ImmunoSensation.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
BarbourA. G.AmanoK.HackstadtT.PerryL.CaldwellH. D. (1982). Chlamydia trachomatis has penicillin-binding proteins but not detectable muramic acid. J. Bacteriol. 151, 420–428.
2
BellandR. J.ZhongG.CraneD. D.HoganD.SturdevantD.SharmaJ.et al. (2003). Genomic transcriptional profiling of the developmental cycle of Chlamydia trachomatis. Proc. Natl. Acad. Sci. U.S.A. 100, 8478–8483. 10.1073/pnas.1331135100
3
Centers for Disease Control Prevention (CDC). (2010). Sexually transmitted diseases treatment guidelines. MMWR Recomm. Rep. 59, 1–110.
4
ContestabileR.PaiardiniA.PascarellaS.Di SalvoM. L.D'aguannoS.BossaF. (2001). l-Threonine aldolase, serine hydroxymethyltransferase and fungal alanine racemase. A subgroup of strictly related enzymes specialized for different functions. Eur. J. Biochem. 268, 6508–6525. 10.1046/j.0014-2956.2001.02606.x
5
FrancoisJ. A.KappockT. J. (2007). Alanine racemase from the acidophile Acetobacter aceti. Protein Expr. Purif. 51, 39–48. 10.1016/j.pep.2006.05.016
6
GaballahA.KloecknerA.OttenC.SahlH. G.HenrichfreiseB. (2011). Functional analysis of the cytoskeleton protein MreB from Chlamydophila pneumoniae. PLoS ONE6:e25129. 10.1371/journal.pone.0025129
7
GhuysenJ. M.GoffinC. (1999). Lack of cell wall peptidoglycan versus penicillin sensitivity: new insights into the chlamydial anomaly. Antimicrob. Agents Chemother. 43, 2339–2344.
8
GriffithsE.GuptaR. S. (2006). Lateral transfers of serine hydroxymethyltransferase (glyA) and UDP-N-acetylglucosamine enolpyruvyl transferase (murA) genes from free-living Actinobacteria to the parasitic chlamydiae. J. Mol. Evol. 63, 283–296. 10.1007/s00239-005-0286-x
9
GuoyaoW. (2013). Amino Acids: Biochemistry and Nutrition. Cleveland, OH: CRC Press; Taylor and Francis Group.
10
HenrichfreiseB.SchieferA.SchneiderT.NzukouE.PoellingerC.HoffmannT. J.et al. (2009). Functional conservation of the lipid II biosynthesis pathway in the cell wall-less bacteria Chlamydia and Wolbachia: why is lipid II needed?Mol. Microbiol. 73, 913–923. 10.1371/journal.pone.0025129
11
KangL.ShawA. C.XuD.XiaW.ZhangJ.DengJ.et al. (2011). Upregulation of MetC is essential for D-alanine-independent growth of an alr/dadX-deficient Escherichia coli strain. J. Bacteriol. 193, 1098–1106. 10.1128/JB.01027-10
12
LambertM. P.NeuhausF. C. (1972). Mechanism of D-cycloserine action: alanine racemase from Escherichia coli. W. J. Bacteriol. 110, 978–987.
13
LiechtiG. W.KuruE.HallE.KalindaA.BrunY. V.VannieuwenhzeM.et al. (2013). A new metabolic cell-wall labelling method reveals peptidoglycan in Chlamydia trachomatis. Nature. [Epub ahead of print]. 10.1038/nature12892
14
McCoyA. J.AdamsN. E.HudsonA. O.GilvargC.LeustekT.MaurelliA. T. (2006). L,L-diaminopimelate aminotransferase, a trans-kingdom enzyme shared by Chlamydia and plants for synthesis of diaminopimelate/lysine. Proc. Natl. Acad. Sci. U.S.A. 103, 17909–17914. 10.1073/pnas.0608643103
15
McCoyA. J.MaurelliA. T. (2005). Characterization of Chlamydia MurC-Ddl, a fusion protein exhibiting D-alanyl-D-alanine ligase activity involved in peptidoglycan synthesis and D-cycloserine sensitivity. Mol. Microbiol. 57, 41–52. 10.1111/j.1365-2958.2005.04661.x
16
McCoyA. J.MaurelliA. T. (2006). Building the invisible wall: updating the chlamydial peptidoglycan anomaly. Trends Microbiol. 14, 70–77. 10.1016/j.tim.2005.12.004
17
MilnerY.WoodH. G. (1976). Steady state and exchange kinetics of pyruvate, phosphate dikinase from Propionibacterium shermanii. J. Biol. Chem. 251, 7920–7928.
18
MoulderJ. W.NovoselD. L.OfficerJ. E. (1963). Inhibition of the growth of agents of the psittacosis group by d-cycloserine and its specific reversal by d-alanine. J. Bacteriol. 85, 707–711.
19
OuelletteS. P.KarimovaG.SubtilA.LadantD. (2012). Chlamydia co-opts the rod shape-determining proteins MreB and Pbp2 for cell division. Mol. Microbiol. 85, 164–178. 10.1111/j.1365-2958.2012.08100.x
20
PatinD.BostockJ.BlanotD.Mengin-LecreulxD.ChopraI. (2009). Functional and biochemical analysis of the Chlamydia trachomatis ligase MurE. J. Bacteriol. 191, 7430–7435. 10.1128/JB.01029-09
21
PatinD.BostockJ.ChopraI.Mengin-LecreulxD.BlanotD. (2012). Biochemical characterisation of the chlamydial MurF ligase, and possible sequence of the chlamydial peptidoglycan pentapeptide stem. Arch. Microbiol. 194, 505–512. 10.1007/s00203-011-0784-8
22
Phillips CampbellR.KintnerJ.WhittimoreJ.SchoborgR. V. (2012). Chlamydia muridarum enters a viable but non-infectious state in amoxicillin-treated BALB/c mice. Microbes Infect. 14, 1177–1185. 10.1016/j.micinf.2012.07.017
23
PilhoferM.AistleitnerK.BiboyJ.GrayJ.KuruE.HallE.et al. (2013). Discovery of chlamydial peptidoglycan reveals bacteria with murein sacculi but without FtsZ. Nat. Commun. 4:2856. 10.1038/ncomms3856
24
ShostakK.SchirchV. (1988). Serine hydroxymethyltransferase: mechanism of the racemization and transamination of D- and L-alanine. Biochemistry27, 8007–8014. 10.1021/bi00421a006
25
SkiltonR. J.CutcliffenL. T.BarlowD.WangY.SalimO.LambdenP. R.et al. (2009). Penicillin induced persistence in Chlamydia trachomatis: high quality time lapse video analysis of the developmental cycle. PLoS ONE4:e7723. 10.1371/journal.pone.0007723
26
StephensR. S.KalmanS.LammelC.FanJ.MaratheR.AravindL.et al. (1998). Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science282, 754–759. 10.1126/science.282.5389.754
27
StromingerJ. L.ItoE.ThrennR. H. (1960). Competitive inhibition of enzymatic reactions by oxamycin. J. Am. Chem. Soc. 82, 998–999. 10.1021/ja01489a058
28
VollmerJ.SchieferA.SchneiderT.JülicherK.JohnstonK. L.TaylorM. J.et al. (2013). Requirement of lipid II biosynthesis for cell division in cell wall-less Wolbachia, endobacteria of arthropods and filarial nematodes. Int. J. Med. Microbiol. 303, 140–149. 10.1016/j.ijmm.2013.01.002
29
WyrickP. B.KnightS. T. (2004). Pre-exposure of infected human endometrial epithelial cells to penicillin in vitro renders Chlamydia trachomatis refractory to azithromycin. J. Antimicrob. Chemother. 54, 79–85. 10.1093/jac/dkh283
Summary
Keywords
chlamydial anomaly, persistence, aberrant bodies, D-alanine, alanine racemase, GlyA, penicillin, D-cycloserine
Citation
De Benedetti S, Bühl H, Gaballah A, Klöckner A, Otten C, Schneider T, Sahl H-G and Henrichfreise B (2014) Characterization of serine hydroxymethyltransferase GlyA as a potential source of D-alanine in Chlamydia pneumoniae. Front. Cell. Infect. Microbiol. 4:19. doi: 10.3389/fcimb.2014.00019
Received
30 October 2013
Accepted
03 February 2014
Published
26 February 2014
Volume
4 - 2014
Edited by
Jan Rupp, University of Lübeck, Germany
Reviewed by
Guido Hansen, University of Lübeck, Germany; Patrick Viollier, University of Geneva, Switzerland
Copyright
© 2014 De Benedetti, Bühl, Gaballah, Klöckner, Otten, Schneider, Sahl and Henrichfreise.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Beate Henrichfreise, Pharmaceutical Microbiology Section, Institute for Medical Microbiology, Immunology and Parasitology, University of Bonn, Meckenheimer Allee 168, 53115 Bonn, Germany e-mail: bhenrich@uni-bonn.de
†Present address: Ahmed Gaballah, Medical Research Institute, Alexandria University, Alexandria, Egypt.
This article was submitted to the journal Frontiers in Cellular and Infection Microbiology.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.